Alton I. Sutnick, M.D., F.A.C.P.; James J. Cerda, M.D.; Philip P. Toskes, M.D.; Veronica E. Coyne, M.D.; W. Thomas London, M.D., F.A.C.P.; Irving Millman, Ph.D.; Baruch S. Blumberg, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The association of Australia antigen (Au(1)) with viral hepatitis led to the hypothesis that it is a hepatitis virus. We have published clinical, epidemiologic, immunologic, and electron microscopic studies supporting this hypothesis. Au(1) is transient in blood of acute hepatitis patients; it is markedly prolonged or persistent in patients with Down's syndrome (30%), leukemia (10%), lepromatous leprosy (10%), and chronic hemodialysis patients (8 of 9). It occurs in 5 to 20% of asymptomatic people in the tropics where family studies indicate an inherited trait causing susceptibility to persistent infection with Au(1). Au(1) persists in 0.1% of the normal U.S. population;
Sutnick AI, Cerda JJ, Toskes PP, et al. Acute and Persistent Australia Antigen in Drug Users.. Ann Intern Med. 1970;72:793. doi: https://doi.org/10.7326/0003-4819-72-5-793_4
Download citation file:
Published: Ann Intern Med. 1970;72(5):793.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use